

Joshi J Alumkal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7792673/publications.pdf>

Version: 2024-02-01

67
papers

4,655
citations

236833

25
h-index

161767

54
g-index

74
all docs

74
docs citations

74
times ranked

6561
citing authors

#	ARTICLE	IF	CITATIONS
1	Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1â2 study. <i>Lancet</i> , The, 2010, 375, 1437-1446.	6.3	972
2	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	0.8	477
3	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	13.5	459
4	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 52810-52817.	0.8	305
5	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	288
6	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
7	A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 480-489.	1.2	170
8	LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4179-E4188.	3.3	160
9	Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16663-16668.	3.3	155
10	Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. <i>Nature Biotechnology</i> , 2022, 40, 527-538.	9.4	128
11	Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. <i>PLoS ONE</i> , 2013, 8, e63563.	1.1	104
12	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	0.9	104
13	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
14	A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5338-5347.	3.2	76
15	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	2.0	66
16	Epigenetic regulation of androgen receptor signaling in prostate cancer. <i>Epigenetics</i> , 2010, 5, 100-104.	1.3	63
17	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.	1.5	51
18	Effect of DNA Methylation on Identification of Aggressive Prostate Cancer. <i>Urology</i> , 2008, 72, 1234-1239.	0.5	46

#	ARTICLE	IF	CITATIONS
19	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 52-63.	3.2	44
20	Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. <i>Clinical Epigenetics</i> , 2015, 7, 128.	1.8	35
21	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. <i>European Urology</i> , 2021, 80, 71-81.	0.9	35
22	Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. <i>Scientific Reports</i> , 2020, 10, 21750.	1.6	34
23	BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. <i>Clinical Cancer Research</i> , 2021, 27, 4923-4936.	3.2	33
24	Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2019, 9, 3823.	1.6	32
25	CT-guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1073-1081.e1.	0.2	30
26	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. <i>Endocrine-Related Cancer</i> , 2021, 28, T51-T66.	1.6	28
27	Multi-Omics Analyses Detail Metabolic Reprogramming in Lipids, Carnitines, and Use of Glycolytic Intermediates between Prostate Small Cell Neuroendocrine Carcinoma and Prostate Adenocarcinoma. <i>Metabolites</i> , 2019, 9, 82.	1.3	27
28	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 610-617.e3.	0.9	25
29	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24
30	BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. <i>Oncogene</i> , 2019, 38, 5658-5669.	2.6	23
31	Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane. <i>Carcinogenesis</i> , 2019, 40, 1545-1556.	1.3	21
32	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.	3.4	21
33	Emerging Therapies in Castrate-Resistant Prostate Cancer. <i>Current Urology Reports</i> , 2010, 11, 152-158.	1.0	20
34	Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4. <i>Neoplasia</i> , 2020, 22, 253-262.	2.3	19
35	De novo neuroendocrine transdifferentiation in primary prostate cancer—a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021, 38, 26.	1.2	18
36	RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 4736-4750.	0.4	18

#	ARTICLE	IF	CITATIONS
37	A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. <i>Epigenetics</i> , 2011, 6, 1248-1256.	1.3	16
38	Diagnostic and Prognostic Utility of a DNA Hypermethylated Gene Signature in Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e91666.	1.1	13
39	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	0.8	12
40	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study. <i>Journal of Clinical Oncology</i> , 2012, 30, 25-25.	0.8	11
41	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4616-4624.	3.2	10
42	Autoantibody Landscape in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6204-6214.	3.2	10
43	Modeling Androgen Deprivation Therapyâ€‘Induced Prostate Cancer Dormancy and Its Clinical Implications. <i>Molecular Cancer Research</i> , 2022, 20, 782-793.	1.5	10
44	Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e191-e198.	0.9	9
45	The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
46	Distinct Epigenetic Mechanisms Distinguish ERG Fusion-Positive and -Negative Prostate Cancers. <i>Cancer Discovery</i> , 2012, 2, 979-981.	7.7	8
47	Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study. <i>Prostate</i> , 2013, 73, 1371-1377.	1.2	7
48	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	2.0	6
49	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4.	1.8	6
50	Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). <i>Cancer Research</i> , 2019, 79, CT095-CT095.	0.4	5
51	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16.	0.8	4
52	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. <i>JCO Precision Oncology</i> , 2020, 4, 1386-1392.	1.5	4
53	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101556.	1.6	4
54	A CHIP in the Armor of Cell-Free DNAâ€‘Based Predictive Biomarkers for Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 111.	3.4	2

#	ARTICLE	IF	CITATIONS
55	Reply to A. Dalla Volta et al. Journal of Clinical Oncology, 2019, 37, 351-352.	0.8	0
56	Sinking Prostate Cancer from Under the Sea. Science Translational Medicine, 2010, 2, .	5.8	0
57	<i>TMPRSS2-ERG</i> , a Mover and a Shaker. Science Translational Medicine, 2010, 2, .	5.8	0
58	Precious Metals. Science Translational Medicine, 2010, 2, .	5.8	0
59	Abrogating Angiogenesis Just Got EZier. Science Translational Medicine, 2010, 2, .	5.8	0
60	Reducing the UnSIRTainty of Alzheimerâ€™s Disease. Science Translational Medicine, 2010, 2, .	5.8	0
61	A New â€œFixâ€ for Cancer. Science Translational Medicine, 2010, 2, .	5.8	0
62	An Expanded Tumor Playing Field. Science Translational Medicine, 2010, 2, .	5.8	0
63	Turning Off the Cancer Switch. Science Translational Medicine, 2010, 2, .	5.8	0
64	Drugging Bugs to Make Chemotherapy Safer. Science Translational Medicine, 2010, 2, .	5.8	0
65	Thinking Outside the Box in Prostate Cancer. Science Translational Medicine, 2010, 2, .	5.8	0
66	JAK and Jumonji: Deadly Playmates. Science Translational Medicine, 2011, 3, .	5.8	0
67	An Epigenetic Road to Genome Instability. Science Translational Medicine, 2011, 3, .	5.8	0